CP even best case senerio which you have no basis to extoll would be three years easy. You are putting out a if /maybe which PPHM and the FDA have not indicated is on the table in any way.
Under both circumstances we do not have the time or money to get the there without diluting current shareholders into oblivion.
The time and money issue does not just hold as a relevant argument it is the ONLY argument for PPHM right now. We are on life support headed back to pre split levels and the next RS. If Ronin fails 6 months to a year at most.
Again what is your best case scenario time and money, if you choose to factor fast tracking which we do not have. What is the time line on that what is the cash burn? What makes you think the FDA is leaning that way other then conjecture based on your evaluation of the benefits of Bavi.
Market Data 
Markets 
AI
